Category Archives: – Biotech

Chapter 1: In the Beginning (How Tony Fauci created the Wuhan virus)

September 13, 2020- by Steven E. Greer, MD

Posted in - Biotech, - Opinion, - Pharma, - Policy, CDC, Congress, Cornell, Emergency medicine, FDA, Genetics, Harvard, Infectious disease, Internal Medicine, NIH | 2 Comments

The “surge in new Wuhan virus cases” is great news

June 26, 2020- by Steven E. Greer, MD I called it, once again. On June 9th, I wrote, “This unprecedented communist-party-like anarchy in

Posted in - Biotech, - Opinion, - Pharma, - Policy, Emergency medicine, Infectious disease, Internal Medicine, Pediatrics, Primary care medicine, Pulmonology | 2 Comments

Joe Piscopo interviews Steven E. Greer, MD: 5-22-2020

May 22, 2020

Posted in - Biotech, - Generics, - Opinion, - Pharma, - Policy, Emergency medicine, Infectious disease, Pulmonology | Leave a comment

Steven E. Greer, MD on OANN discussing virus therapies

April 16, 2020

Posted in - Biotech, - Generics, - Opinion, - Pharma, CDC, CMS, Congress, Emergency medicine, FDA, Geriatrics, Infectious disease, Internal Medicine, NIH, Pediatrics, Primary care medicine, Pulmonology, VA | Leave a comment

Are there any medications to treat coronavirus?

(Also: How infectious and lethal is this Coronavirus COVID-19 compared to regular “flu”?) February 27, 2020- by Steven E. Greer, MD Gilead makes a not-yet-approved antiviral drug called remdisivir and it is being tested right

Posted in - Biotech, - Opinion, - Pharma, - Policy, CDC, Congress, FDA, Geriatrics, Infectious disease, Internal Medicine, NIH, Primary care medicine | 2 Comments

The only thing we have to fear…is fear itself

March 13, 2020- by Steven E. Greer, MD Holy cow. The PGA Tour cancelled the Players Championship due to fears over the coronavirus.

Posted in - Biotech, - Medical Devices, - Opinion, - Pharma, - Policy, CDC, CMS, Congress, Emergency medicine, FDA, Infectious disease, Internal Medicine, NIH, Primary care medicine, Pulmonology, VA | Leave a comment

60 Minutes creates another publicist-paid puff-piece for an unethical medical researcher

December 8, 2019- by Steven E. Greer, MD CBS’ 60 Minutes featured an extremely unethical PhD medical researcher at Harvard named George

Posted in - Biotech, - Opinion, - Pharma, - Policy, CDC, Congress, FDA, Genetics, NIH | Leave a comment

The FDA pathway for biosimilar drug approvals

March 26, 2015- Interviewed by Steven E. Greer,

Posted in - Biotech, - Generics, FDA | Leave a comment

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

February 27, 2017- interviewed by Steven E. Greer, MD We interviewed Joaquim Bellmunt, MD, PhD, the Director of the Bladder Cancer Center at Dana-Farber,

Posted in - Biotech, - NEJM, - Pharma, Harvard, Oncology | Leave a comment

Preventing HIV infection

July 28, 2014- Interviewed by Steven E. Greer, MD Rajesh Tim Gandhi, MD of the Massachusetts General Hospital discusses the NEJM review paper he co-wrote

Posted in - Biotech, - NEJM, - Pharma, General surgery, Harvard, Infectious disease, Primary care medicine | Leave a comment

Paul Richardson, MD: Current Therapies for Multiple Myeloma

December 15, 2015- Interviewed by Steven Greer, MD Dr. Paul Richardson, Clinical Director of the Multiple Myeloma Center at Harvard’s Dana-Farber

Posted in - Biotech, - Pharma, Harvard, Oncology | Leave a comment

Triple Therapy for Cystic Fibrosis

October 18, 2018- interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Pharma, FDA, Genetics, Infectious disease, Internal Medicine, National Jewish Health, Pediatrics, Pulmonology | Leave a comment

BRAF and MEK combos for melanoma

Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr.  Ribas last year.

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

Google wants your medical records

December 19, 2013- Interviewed by Steven E. Greer, MD In Part 3 of our interview with Robert Klitzman, MD, ethics professor at Columbia University,

Posted in - Biotech, - Policy, Columbia, FDA, Genetics | Leave a comment

Google’s Larry Page wants your medical records to be public for “research”

March 20, 2014-By Steven E. Greer, MD Charlie Rose interviewed Google founder Larry Page at the 2014 TED conference. During the talk, Mr.

Posted in - Biotech, - Medical Devices, - Opinion, Congress, Genetics | Leave a comment

Review of immunotherapy and targeted therapy

June 17, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma, to go over the

Posted in - Biotech, - Pharma, Oncology, UCLA | Leave a comment

The Year in Review: 2018

December 29, 2018- by Steven E. Greer, MD The biggest stories this year related

Posted in - Biotech, - Generics, - Medical Devices, - Opinion, - Pharma, - Policy, - Reviews, books, devices, - The Weekly Summary | Leave a comment

Insurance companies are not paying for Repatha and Praluent

Update November 2, 2018- Amgen slashed the annual cost of this drug to $6,000.

Posted in - Biotech, - Pharma, - Policy, Cardiac surgery, Cardiology, Henry Ford, Primary care medicine | Leave a comment

Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis

January 31, 2017- Interviewed by Steven E. Greer, MD

Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas | Leave a comment

KIT inhibition by Gleevec (imatinib) for severe asthma

May 26, 2017- Interviewed by Steven E. Greer, MD Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers

Posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology | Leave a comment